BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 7978890)

  • 1. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.
    Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; Reubi JC; Lamberts SW
    Ann N Y Acad Sci; 1994 Sep; 733():416-24. PubMed ID: 7978890
    [No Abstract]   [Full Text] [Related]  

  • 2. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
    Pauwels S; Leners N; Fiasse R; Jamar F
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
    [No Abstract]   [Full Text] [Related]  

  • 3. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
    Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
    [No Abstract]   [Full Text] [Related]  

  • 4. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
    Chiti A; Spinelli A; Bombardieri E
    Radiol Med; 1997 Oct; 94(4):362-70. PubMed ID: 9465244
    [No Abstract]   [Full Text] [Related]  

  • 5. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
    Banzo J; Abós MD; Prats E; García F; Razola P
    Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
    Modlin IM; Cornelius E; Lawton GP
    Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor imaging in patients with neuroendocrine tumors: preoperative and postoperative scintigraphy and intraoperative use of a scintillation detector.
    Ahlman H; Tisell LE; Wängberg B; Nilsson O; Forssell-Aronsson E; Fjälling M
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):21-8. PubMed ID: 7992076
    [No Abstract]   [Full Text] [Related]  

  • 8. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
    Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
    Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor: scintigraphy and radionuclide therapy.
    Krenning EP; Kooij PP; Pauwels S; Breeman WA; Postema PT; De Herder WW; Valkema R; Kwekkeboom DJ
    Digestion; 1996; 57 Suppl 1():57-61. PubMed ID: 8813472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
    Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.
    Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC
    J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
    Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
    Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Scintigraphy of somatostatin receptors in gastropancreatic tumors].
    Mansi L
    Radiol Med; 1998 Mar; 95(3):264. PubMed ID: 9638181
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
    Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
    J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome.
    Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; de Herder WW; Reubi JC; Lamberts SW
    Digestion; 1994; 55 Suppl 3():54-9. PubMed ID: 7698538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
    Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
    Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors.
    Janson ET; Kälkner KM; Eriksson B; Westlin JE; Oberg K
    Nucl Med Biol; 1999 Nov; 26(8):877-82. PubMed ID: 10708300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor imaging.
    Kwekkeboom DJ; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):84-91. PubMed ID: 11965603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indium 111 octreotide scintigraphy in angiofibroma.
    Guneri EA; Degirmenci B; Durak H; Ikiz AO; Derebek E; Sutay S
    Otolaryngol Head Neck Surg; 1998 Jan; 118(1):137-9. PubMed ID: 9450844
    [No Abstract]   [Full Text] [Related]  

  • 20. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.